Isolation of two forms of decay-accelerating facto...[Biochim Biophys Acta. 1991]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Biochim Biophys Acta. 1991 Jul 8;1074(2):326-30. Links

Isolation of two forms of decay-accelerating factor (DAF) from human urine.

Nakano Y, Sugita Y, Ishikawa Y, Choi NH, Tobe T, Tomita M.

Department of Physiological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.

Decay-accelerating factor (DAF) was purified from human pooled urine by conventional techniques. The urine DAF was separated into two peaks, pool I and pool II, by gel chromatography. DAF-U1 was isolated from pool I by hydrophobic chromatography, and DAF-U2 from pool II by anti-DAF IgG column. The specific activities of DAF-U1 and DAF-U2 to decay membrane-phase C5 convertase were about 3% and 70% of membrane form DAF, respectively. However, both urine DAFs revealed a similar activity to each other and slightly higher activity than that of membrane form DAF in decay-accelerating fluid-phase C3 convertase of the alternative pathway.

PMID: 1712233 [PubMed - indexed for MEDLINE]

Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Immunology. 1988 Jul; 64(3):369-74.

[Immunology. 1988]
Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
J Exp Med. 1995 Jan 1; 181(1):151-9.

[J Exp Med. 1995]
The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
J Exp Med. 1987 Nov 1; 166(5):1221-8.

[J Exp Med. 1987]
The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
J Immunol. 1990 Dec 1; 145(11):3836-41.

[J Immunol. 1990]
Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
J Immunol. 1985 Oct; 135(4):2661-7.

[J Immunol. 1985]
» See reviews... | » See all...

Cited by 4 PubMed Central articles

Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Invest Ophthalmol Vis Sci. 2000 Dec; 41(13):4195-202.

[Invest Ophthalmol Vis Sci. 2000]
Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC).
Inaba T, Mizuno M, Ohya S, Kawada M, Uesu T, Nasu J, Takeuchi K, Nakagawa M, Okada H, Fujita T, et al. Clin Exp Immunol. 1998 May; 112(2):237-41.

[Clin Exp Immunol. 1998]
Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Am J Pathol. 1996 Jul; 149(1):129-42.

[Am J Pathol. 1996]
» See all...

Recent Activity

Clear Turn Off Turn On

Isolation of two forms of decay-accelerating factor (DAF) from human urine.Isolation of two forms of decay-accelerating factor (DAF) from human urine.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

Isolation of two forms of decay-accelerating factor (DAF) from human urine.

Related articles

Cited by 4 PubMed Central articles

Recent Activity